ClearPoint Neuro (CLPT) closed at $10.56 on Oct 28, 2026, up 9.0% on the day. The stock is down 10.3% over the past month, down 27.6% over three months, down 22.8% year to date and down 58.5% over the past year. It trades 57.7% below its 52-week high of $24.98 and 27.7% above its 52-week low of $8.27. The close sits below its 50-day moving average ($12.70) and below its 200-day moving average ($13.00).
No — the Oct 28, 2026 close of $10.56 is 18.8% below the 200-day average of $13.00.
CLPT closed 57.7% below its 52-week high of $24.98.
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
